FilingsTodayHana Pharm.
At a glance
Hana Pharm. filed 34 disclosures in the last 12 months, including 7 insider and 2 buyback. The most recent key filing was on Aug 27.
Revenue for 2025 was ₩240B, up 6.3% on 2024. Operating margin was 10.8% against 11.2% a year earlier. Debt was 33% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩123B and operating profit of ₩14.4B.
The 2025 annual report lists 706 employees with an average tenure of 6.3 years and average pay of ₩53M, #1312 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩146M each on average. It paid ₩260 per common share in cash dividends, against ₩510 a year earlier (-49%). 조동훈 and related parties held 57.71% at year end.
From the 2025 annual report
Staff: 706 (540 men, 166 women), of whom 33 on fixed-term contracts. Total pay for the year: ₩37.3B. Directors and auditors: 8, paid ₩1.2B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩260 | ₩510 | ₩510 |
| Payout ratio | 52.1% | 41.5% | 39.5% |
| Yield (as filed) | 2.20% | 4.60% | 3.60% |
| Total cash dividends | ₩4.6B | ₩8.8B | ₩8.8B |
Largest shareholder
조동훈 holds 25.29%; with 9 related parties the group holds 57.71% of common shares at year end.
Individuals paid ₩500M or more
| 조경일 명예회장 | ₩700M |
Auditor: 대성회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.